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To induce strong protective immunity against very virulent infectious bursal disease virus (vvIBDV) in chickens, two viral
vector systems, Marek’s disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV), were
used. Most of chickens vaccinated with the rFPV or rMDV alone, or vaccinated simultaneously with both at their hatch
(rMDV-rFPV1d), were protected against developing clinical signs and mortality; however, only zero to 14% of the chickens were
protected against gross lesions. In contrast, gross lesions were protected in 67% of chickens vaccinated primarily with the
rMDV followed by boosting with the rFPV 2 weeks later (rMDV-rFPV14d). Protection against the severe histopathological
lesions of rFPV, rMDV, rMDV-rFPV1d, and rMDV-rFPV14d vaccine groups were 33, 42, 53, and 73%, respectively. Geometric
mean antibody titers to VP2 of chickens vaccinated with the rFPV, rMDV, rMDV-rFPV1d, and rMDV-rFPV14d before the challenge
were 110, 202, 254, and 611, respectively. Persistent infection of the rMDV in chickens after the booster vaccination with rFPV
was suggested by detection of the rMDV genes from peripheral blood lymphocyte DNA at 28 weeks of age. These results
indicate that the dual-viral vector approach is useful for quickly and safely inducing strong and long-lasting protective
immunity against vvIBDV in chickens. © 2000 Academic PressINTRODUCTION
Infectious bursal disease virus (IBDV) causes consid-
erable economic loss in the poultry industry by inducing
severe clinical signs, immunosuppression, and high
mortality (^50%) in chickens (Lukert and Saif, 1997).
B-lymphocytes of the bursa of Fabricius (BF) are target
cells for IBDV infection. IBDV is a member of the Birna-
viridae family, whose genome consists of two segments
of double-stranded RNA (dsRNA) (Kibenge et al., 1988):
segment B encodes the putative dsRNA polymerase VP1
(Spies et al., 1987), and segment A encodes two proteins,
precursor polyprotein and a small protein (VP5). The
precursor polyprotein is processed to three mature viral
proteins, VP2, VP3, and VP4. VP2 is a conformational
host-protective antigen (Azad et al., 1991; Bechet et al.,
1988; Fahey et al., 1989; Kibenge et al., 1988) and also an
apoptotic inducer (Fernandez-Arias et al., 1997). VP3 is a
group-specific antigen; however, the protective role has
not yet been discovered (O¨ppling et al., 1991). VP4 may
be a viral protease. VP5 is not essential for viral replica-
tion (Mundt et al., 1997), and the VP5-inactivated mutant
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257virus induced a high level of protective immunity in chick-
ens despite an absence of BF lesions (Yao et al., 1998).
IBD has been controlled by live IBDV vaccines (Ismail
and Saif, 1991); however, it is difficult to protect field
chickens with the maternal antibodies by the live vac-
cines (Ismail and Saif, 1991; Lukert and Saif, 1997; Tsuka-
moto et al., 1995b). In addition, live vaccines induce
moderate bursal atrophy (Muskett et al., 1985), and the
antigenic or pathogenic characters are not stable. Pas-
sages of live IBDV vaccines to chickens have been
shown to increase the virulence (Muskett et al., 1985).
Thus, as a new generation of vaccine, safer and more
efficacious IBD vaccines must be studied.
There are several viral vector systems including retro-
virus, poxvirus, herpesvirus, adenovirus, and adeno-as-
sociate virus, which are useful for gene therapy and
recombinant vaccines, as well as in vitro expression
systems. Research on the viral vector-based polyvalent
vaccines is especially required for livestock to control
several important infectious diseases. Three live vac-
cine-based viral vectors of chickens lead this research
field: Marek’s disease virus (MDV) (Cantello et al., 1991),
herpesvirus of turkey (HVT) (Morgan et al., 1992), and
fowlpox virus (FPV) (Bayliss et al., 1991). Both MDV and
HVT vectors are developed for the induction of long-term
protective immunity in chickens because both vectors
are herpesviruses, whereas the FPV vector is used to
quickly induce protective immunity in chickens. These
0042-6822/00 $35.00
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258 TSUKAMOTO ET AL.viral vector-based recombinant vaccines are safe for
chickens and have no risk of producing antigenic/patho-
genic variants because of subunit-type vaccines. Their
low vaccine efficacy, however, is a hindrance for practi-
cal use in the field when compared to commercial live
vaccines (Ismail and Saif, 1991; Tsukamoto et al., 1995b).
For example, viral vector-based recombinant vaccines
hardly protected against the formation of gross BF le-
sions when challenged with very virulent IBDV (vvIBDV),
although they provided protection against the develop-
ment of clinical signs and mortality (Bayliss et al., 1991;
Darteil et al., 1995; Tsukamoto et al., 1999). Further stud-
es are required not only to develop highly efficacious
ecombinant vaccines but also to know how to use them
ffectively.
In this study, we compared the efficacy of two viral
ectors, rMDV and rFPV, against vvIBDV, and tested a
ew vaccine regimen using them to induce a higher level
rotective immunity. This study demonstrated that the MDV
ector system induced a higher level protective immunity
han the FPV vector system, and the rMDV-induced protec-
ive immunity was significantly enhanced by subsequent
accination with the rFPV. The anti-VP2 antibody kinetic
urve of the rMDV-rFPV group was higher than that of the
MDV alone and almost comparable with that of live IBDV
accine for 28 weeks. The dual-viral vector approach is a
ew experimental method for inducing strong and long-
asting protective immunity against a wide range of infec-
ious diseases of animals. The approach may be applicable
o other viral vector combinations.
RESULTS
FIG. 1. Characterization of the rFPV expressing the IBDV VP2. (A) PC
ith the wild-type FPV, rFPV, wild-type MDV, or rMDV 24 h after inocul
ene amplification by PCR. Plasmid DNA containing the VP2 gene, pV
nfected with FPV, rFPV, or IBDV J1 strain were harvested 24 h after i
ytopathic effect became 111. The cells were processed by SDS-PAG
detected with anti-IBDV rabbit serum and horseradish peroxidase-lab
(ECL) Western blotting detection reagents (Amersham).Analysis of constructed rFPV. Insertion of the VP2 ex-
ression cassette into the genome of FPV was deter-ined by PCR amplification of the VP2 gene. As shown in
ig. 1A, the expected size of the DNA fragment (1.3 kbp)
as detected from DNA prepared from the culture fluid of
he rFPV-infected CEF culture, whereas no band was
etected in the wt FPV-infected cell culture fluid. The VP2
NA size was identical to that of the rMDV (Fig. 1A).
Western blotting analysis (Fig. 1B) confirmed synthesis
f the VP2 protein in CEF cells infected with rFPV. The
ize of VP2 expressed by the rFPV was about 42 kDa,
hich was identical to that of VP2 expressed by the
MDV. These results indicated the expected construction
f the rFPV.
Protection against clinical signs and mortality. All of
he chickens vaccinated with the rFPV, rMDV, rMDV-
FPV1d, or rMDV-rFPV14d were challenged with vvIBDV at
30 days of age. As a result, each recombinant vaccine or
each combination group conferred protection against
clinical signs and mortality to all of the vaccinated chick-
ens except for a chicken vaccinated with the rMDV
alone, which exhibited clinical signs and died of IBD.
Live vaccine IBDV-A conferred full protection against the
challenge. All of the chickens in the challenge control
groups succumbed to the infection; the morbidity and
mortality were 100 and 60%, respectively.
Protection against gross lesions. As shown in Fig. 2A,
the severe gross BF lesions were protected at a low
frequency in chickens vaccinated with the rFPV (0%,
0/15), rMDV (14%, 2/14), or rMDV-rFPV1d (13%, 2/15) after
he challenge. In contrast, 67% (10/15) of the chickens
accinated with the rMDV-rFPV14d were protected against
gross BF lesions. Ten percent or 100% of chickens vac-
cinated with the commercial vaccine IBDV-A or IBDV-C
ysis of the rFPV. Cellular DNAs were obtained from CEF cells infected
ith the Qiagen blood kit. The DNAs were used as a template for VP2
s used as the control. (B) Western blot analysis of the rFPV. CEF cells
ion. CEF cells infected with MDV or rMDV were harvested when the
sis and transferred to nitrocellulose membranes. The VP2 protein was
nti-rabbit IgG goat immunoglobulin by enhanced chemiluminescenceR anal
ation w
P2, wa
noculat
E analyhad mild BF gross lesions, respectively; the mild gross
lesions might be side effects of the vaccine strain itself
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259DUAL-VIRAL VECTORS FOR INFECTIOUS BURSAL DISEASE VIRUS(Tsukamoto et al., 1995b). All chickens in the challenge
ontrol group had severe gross lesions (Fig. 2A).
Protection against histopathological lesions. As shown
in Fig. 2B, the average histopathological BF lesion score
of chickens vaccinated with the rFPV, rMDV, or rMDV-
rFPV1d was approximately 4 (4.3, 3.6, and 3.7, respec-
ively). In contrast, the score of chickens vaccinated with
he rMDV-rFPV14d was 1.7, which was close to that of the
commercial vaccine IBDV-A (1.2). Commercial vaccine
IBDV-C and the challenge control groups had BF lesion
scores of 4.0 and 5.0, respectively.
Our protection criteria mean that chickens with BF
FIG. 2. Protective efficacy against vvIBDV of each vaccine group in
istopathological BF lesions. The rFPV was inoculated into 1-day-old o
hickens. The rMDV was inoculated into chickens alone or in combina
noculated into SPF chickens at 20 days of age. These vaccinated chick
gg infective dose/chicken). The gross lesions and histopathological
istopathological lesion scores below 4 were considered protected a
esion scores in each vaccine group. A commercial vaccine, IBDV-C, w
ogical lesion score was tested to see the side effect 7 days after thelesion scores of 0–4 were considered protected his-
topathologically (Tsukamoto et al., 1999). According tothis criteria, protective efficacy against the histopatho-
logical BF lesions of the rFPV, rMDV, rMDV-rFPV1d, and
rMDV-rFPV14d vaccine groups was 33, 42, 53, and 73%,
espectively, whereas that of the commercial vaccine
BDV-A was 100% (Fig. 2A).
The chickens vaccinated with the rMDV-rFPV14d were
divided into two groups based on the BF lesion scores:
about 34 of the chickens had no or mild BF lesions
(scores 5 0–2), whereas 14 of the chickens still had
severe BF lesions (score 5 5) (Fig. 2B).
Antibody responses against VP2 before the challenge.
The geometric mean (GM) EIA antibody titers against
s. (A) Percentage of chickens that were protected against gross and
y-old SPF chickens, and the rMDV was inoculated into 1-day-old SPF
ith the rFPV as previously shown. A commercial vaccine, IBDV-A, was
re challenged at 30 days of age with vvIBDV Ehime/91 strain (105 50%
scores were determined 7 days after the challenge. Chickens with
ibed under Materials and Methods. (B) Ratio of the histopathological
arately inoculated into 30-day-old SPF chickens, and the histopatho-
ation. The lesion score data were added to the figure.chicken
r 14-da
tion w
ens we
lesion
s descrVP2 in chickens vaccinated with the rFPV, rMDV, or
rMDV-rFPV1d were 110, 202, or 254, respectively (Fig. 3A).
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260 TSUKAMOTO ET AL.In contrast, chickens vaccinated with the rMDV-rFPV14d
had the higher GM antibody titer (EIA antibody titer 5
611), which was close to the protection level (EIA anti-
body titer 5 640) as described below. However, two
hickens in the rMDV-rFPV14d group still had low antibody
titers (40 or 160). The commercial IBDV-A vaccine pro-
duced a higher level of anti-IBDV antibodies (^1280).
The AGP test results were similar to the EIA test results.
The AGP antibody-positive chickens were detected at a
higher frequency (80%, 12/15) in the rMDV-rFPV14d group
han the other three vaccine groups: 0% (0/15), 21% (3/14),
nd 27% (4/15) in the rFPV, rMDV, and rMDV-rFPV1d
groups, respectively. The AGP antibodies were detected
in all of the chickens vaccinated with the IBDV-A vaccine
(10/10).
Since both rMDV and rFPV expressed VP2, the four
FIG. 3. Humoral immune responses to VP2 of each vaccine group. The
era were collected at 30 days of age before the challenge. See the lege
roups. Geometric mean EIA antibody titers to VP2 of each vaccine group
hown. (B) Correlation between the EIA antibody titers to VP2 and the pro
rom chickens in each vaccine group dealt with one group since both reco
hat were protected against gross and histopathological BF lesions in therecombinant vaccine groups were considered in the
same criteria to determine a relationship between serumantibody levels to VP2 and protection against histopatho-
logical BF lesions. As shown in Fig. 3B, there is a clear
correlation between the two. The EIA antibody titers of
320 or below did not protect chickens efficiently against
gross (5%, 2/42) and histopathological BF lesions (33%,
14/42). In contrast, the antibody titers of 640 or higher
conferred protection at a high frequency against gross
(70%, 12/17) and histopathological BF lesions (94%, 16/
17). The presence of the AGP antibody to VP2 was also
associated with approximately 70 and 90% protection
against gross and histopathological BF lesions, respec-
tively (Fig. 3C).
Persistence of the humoral immunity in chickens. The
humoral immunity level was determined to know how
long the protective level of the AGP antibody to VP2 was
maintained in chickens after vaccination with the IBDV-A,
14d
ns were vaccinated as described under Materials and Methods, and the
ig. 2 for details. (A) Comparison of antibody titers to VP2 among vaccine
rcentage of chickens in each group that were positive in the AGP test are
against gross and histopathological BF lesions. All of the sera collected
t vaccines expressed the same VP2 antigen. (C) Percentage of chickens
ntibody positive or negative chicken groups.chicke
nd to F
and pe
tectionrMDV alone, or rMDV-rFPV . The AGP antibody was
detected at a higher frequency at 4 or 8 weeks of age
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261DUAL-VIRAL VECTORS FOR INFECTIOUS BURSAL DISEASE VIRUSthan other periods in all three vaccine groups. The AGP
antibody to VP2 was detected from 4 to 20 weeks of age
in chickens vaccinated with the rMDV-rFPV14d with a
range of 20–80%, whereas it was detected only from 4 to
8 weeks of age in the rMDV group (20%). The AGP
antibody kinetic curve of the rMDV-rFPV14d group was
similar to that of the current live vaccine group IBDV-A,
which induced the AGP antibody from 4 to 16 weeks of
age with a range of 20–100% (Fig. 4A). In contrast, there
was no significant difference in EIA anti-MDV antibody
titers between the two recombinant vaccine groups (Fig.
4B). The EIA anti-MDV antibody reached a peak level at
8–12 weeks of age, and the antibody level was main-
tained throughout the experiment in both vaccine groups.
No anti-MDV antibody was detected in chickens vacci-
nated with IBDV-A throughout the experiment.
To determine whether the rMDV persisted in vacci-
nated chickens after the booster vaccination, both first
and nested PCR analyses to detect IBDV VP2 and MDV
US2 genes were performed on peripheral blood lympho-
cyte DNA at 28 weeks of age. DNA samples collected
from chickens vaccinated with the rMDV alone were
used as the control. As shown in Table 1 and Fig. 5, the
IBDV VP2 gene was detected in 0% (0/5) and 80% (4/5) of
chickens in the rMDV-rFPV14d group by first and nested
PCR analyses. Chicken No. 10 in the rMDV-rFPV14d group
as positive in the subsequent nested PCR analysis. The
P2 gene was also detected in 80% (4/5) and 100% (5/5)
f chickens in the rMDV group by the first and nested
CR analyses, respectively. PCR analysis data for the
DV US2 gene were almost the same as those of the
BDV VP2. These results indicated that the rMDV infected
FIG. 4. Persistence of humoral immune responses in chickens for 28
of the AGP antibody to VP2 in these chickens. Percentage of chickens t
to MDV in these chickens. The geometric mean antibody titer to MDV
dilution which showed positive reaction.ersistently in chickens for at least 26 weeks after the
ooster vaccination.DISCUSSION
Recombinant herpesvirus or poxvirus vaccines offer
reat hope for improved immunization against a wide
ange of pathogens because both vectors are safe, sta-
le, and can express multiple antigens. However, by
hemselves they can elicit only a low level of protective
mmunity so far. All of the recombinant viral vector vac-
ines expressing IBDV VP2 (rFPV, rHVT, and rMDV) failed
o protect the development of gross lesions when chal-
enged with vvIBDV even though they were able to pro-
ect chickens against developing clinical signs and mor-
ality (Bayliss et al., 1991; Darteil et al., 1995; Heine and
oyle, 1993; Tsukamoto et al., 1999). So, we have focused
n the development of a new vaccine regimen based on
oth herpesvirus and poxvirus vector systems, rMDV and
after vaccination with IBDV-A, rMDV, or rMDV-rFPV14d. (A) Persistence
e positive in the AGP test is shown. (B) Persistence of the EIA antibody
n. Each serum antibody titer is expressed as the reciprocal of serum
TABLE 1
Detection of rMDV Genes from Peripheral Blood Lymphocyte DNA
of Chickens Vaccinated with the rMDV or rMDV-rFPV14d Using First
nd Nested PCR Analyses
PCR
Chickens vaccinated with
rMDV rMDV-rFPV14d
IBDV VP2a MDV US2 IBDV VP2 MDV US2
First 4/5b 4/5 0/5 1/5
ested 5/5 5/5 4/5 4/5
Note. Chickens were vaccinated with the rMDV at 1 day of age, and
alf of them were boosted with the rFPV at 14 days of age. The
eripheral blood lymphocyte DNA was collected at 28 weeks of age
rom the chickens and used as templates for PCR analysis.weeks
hat wera Gene amplified.
b No. of positive chickens/number tested.
e V US2
P
262 TSUKAMOTO ET AL.rFPV. To our knowledge, this is the first report describing
a dual-viral vector approach in order to generate a high
level of protective immunity in animals. Our study
showed that a single administration of both viral vectors
was sufficient to induce a high level of the protective
immunity against vvIBDV. Eleven of 15 chickens in the
rMDV-rFPV14d group were histopathologically protected,
and 10 of them were almost protected against the vvIBDV
infection because their BF lesion scores were zero or 1.
This high efficacy was not achieved by the simultaneous
vaccination with the rMDV and the rFPV at their hatch,
but achieved by inoculation with the rFPV 2 weeks later
after the primary vaccination with the rMDV. This result
suggested that this high efficacy might be due to a
booster phenomenon. This is different from herpes-
primed/herpes-boosted or pox-primed/pox-boosted vac-
cine regimens. Two times vaccination with the rFPV
FIG. 5. Detection of rMDV genes by PCR from peripheral blood lymp
rMDV alone or rMDV-rFPV14d. (A) Position of IBDV VP2 and MDV U
lectrophoresis analysis of PCR products. Plasmid p2EG containing MD
CR products are indicated by arrows.expressing VP2 did not protect from BF gross lesions
(Bayliss et al., 1991). Also, it is unlikely that the primaryimmune responses were enhanced by readministration
with the rMDV because the rMDV vaccination inhibited
replication of even vvMDV in chickens (Tsukamoto et al.,
1999). Only consecutive immunization strategy involving
priming with one viral vector and boosting with the other
viral vector is a key to triggering a strong booster phe-
nomenon in animals. Recently, consecutive immuniza-
tion strategies have been reported in human immunode-
ficiency virus (HIV). Immunization involving priming with
DNA (two administrations) followed by boosting with
rFPV expressing HIV antigens induced greater HIV-spe-
cific humoral and cellular immunity in macaques than
either vaccine alone (Kent et al., 1998). DNA-priming and
recombinant protein-boosting vaccine regimens also
elicited neutralizing antibodies to HIV in rabbits (Rich-
mond et al., 1998). Our herpesvirus-primed and poxvirus-
boosted vaccine regimen is theoretically advantageous
DNA collected at 28 weeks of age from chickens vaccinated with the
nes amplified by first and nested PCR analyses. (B) Agarose gel
and IBDV VP2 genes was used as the control template. The expectedhocyte
S2 geto these strategies because of quick and long-lasting
induction of a high level of protective immunity in animals.
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263DUAL-VIRAL VECTORS FOR INFECTIOUS BURSAL DISEASE VIRUSThe presence of low responders is a weak aspect of
subunit-type vaccines. The low responders against VP2
were confirmed in the rMDV group as previously de-
scribed (Tsukamoto et al., 1999). One chicken in the
MDV group succumbed to the infection after showing
linical IBD. It was not determined whether such low
esponders resulted from low growth efficiency of the
MDV in chickens, weak immunological responses to the
ubunit antigen VP2, or high susceptibility to IBDV (Bum-
tead et al., 1993). At least, it is significant that some low
esponders were promoted to the well responders by the
ooster vaccination with the rFPV; protection efficacy
gainst gross and histopathological lesions and anti-
ody titers against VP2 increased to 4.8, 1.7, and 3.0
imes as high as those by the rMDV alone, respectively
Table 2). This study also shows that the efficacy of the
FPV was lower than that of the rMDV (Table 2). In
ddition, the rFPV may be a more powerful booster
accine than live IBDV vaccines because live IBDV vac-
ines are highly sensitive to neutralizing antibody to
BDV (Tsukamoto et al., 1995b). Therefore, it is preferable
to use the rFPV as a booster vaccine. Scabbing was
observed in chickens vaccinated with rFPV at the injec-
tion site 6 days after the vaccination, which was evi-
dence of a successful vaccination against fowlpox (FP).
It was previously shown that the rMDV vaccination com-
pletely suppressed tumor development caused by
vvMDV in chickens (Tsukamoto et al., 1999). Therefore, it
is likely that our vaccine regimen should be effective for
MD, FP, and IBD, and other infectious diseases could be
added to the dual-viral vector approach. Both MDV and
FPV vector vaccines have been used for layers and
parent chickens for more than 20 years worldwide. Both
rMDV and rFPV may be more resistant to the maternal
antibodies to IBDV than the current IBDV live vaccines.
Thus theoretically, there is no major obstacle to applying
this approach to layers and parent chickens. Although
further studies are required to improve the efficacy of
both vaccines to achieve full protection, the goal may not
be far.
Lifetime persistence of protective immunity in animals
is a key theme for the herpesvirus vectors; however, the
study is limited. An MDV-based recombinant using an
T
Comparison of Vaccine Efficacy against vv
Vaccine efficacy rMDV
Protection against gross lesions 1
Protection against histopathological lesions 1
Level of antibody to VP2 1SV40 late promoter maintained a protective level of an-
tibodies to NDV F protein for more than 24 weeks (Sak-
s
laguchi et al., 1998). The protective level of AGP antibod-
ies to VP2 was detected in 80% of chickens vaccinated
with the rMDV-rFPV14d, but the antibody gradually de-
clined and had not been detected since 24 weeks of age.
One possible explanation of this antibody decline is that
the rFPV-booster vaccination quickly enhanced the pri-
mary immune responses; however, the immunity level
then gradually declined to a level equal to that induced
by the rMDV alone. This antibody decline may not be
disappointing because the decline pattern was also ob-
served in chickens vaccinated with IBDV-A; the chickens
were protective throughout their lives (Fig. 4A). In addi-
tion, adult chickens (more than 20 weeks of age) are
resistant to IBDV because of atrophy of the BF, a target
organ for IBDV. It is encouraging that both the IBDV VP2
and the MDV US2 genes of the rMDV were detected from
peripheral blood lymphocyte DNA of chickens vacci-
nated with rMDV-rFPV14d at 28 weeks of age by nested
CR analyses (Table 1, Fig. 5). We did not attempt to
eisolate the rMDV from the chickens. It is likely that
espite the booster vaccination with the rFPV at 2 weeks
f age, the rMDV might persist in the vaccinated chick-
ns for at least 180 days. The rMDV DNA level, however,
as lower in the rMDV-rFPV14d group than in the rMDV
group, and the AGP antibody to VP2 had not been de-
tected from 24 weeks of age. The rMDV must be im-
proved to persist more efficiently in chickens after the
booster vaccination. Glycoprotein promoters derived
from herpesvirus are believed to help persistent infection
of the recombinant herpesvirus vaccines in animals.
Pseudorabies virus recombinant based on a gG pro-
moter or MDV recombinant based on a gB promoter to
express a foreign antigen induced highly efficient pro-
tection in animals (Sonoda et al., 1996; Van Zijl et al.,
1991).
Serum-neutralizing antibodies correlate with the pro-
tection in IBDV infection (Lukert and Saif, 1997). This
study showed a high degree of correlation between the
serum antibody level to VP2 and the protective efficacy
against vvIBDV when compared with our previous study
(Figs. 3B and 3C) (Tsukamoto et al., 1999). The high level
f the EIA (^1:640) or AGP antibodies to VP2 correlated
ith approximately 70% protection against the gross le-
f Four Vaccine Groups with That of rMDV
Chickens vaccinated with
V rMDV-rFPV1d rMDV-rFPV14d IBDV-A
0.9 4.8 6.4
1.3 1.7 2.4
1.2 3.0 6.3ABLE 2
IBDV o
rFP
0.0
0.8ions and 90% protection against the histopathological
esions. The high level of the antibodies may play a role
G
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264 TSUKAMOTO ET AL.in prevention against vvIBDV infection. The reason for
the higher level of the antibodies in this study than in our
previous study is not known; however, this difference
might be due to a different SPF chicken line used be-
tween the experiments. In addition, as previously de-
scribed (Bayliss et al., 1991; Tsukamoto et al., 1999), a
vital role of the cellular immunity to VP2 in vvIBDV pro-
tection was suggested. Protection against mortality and
gross lesions was achieved in some chickens despite
the low level of the antibodies to VP2 (Fig. 3B). It remains
to be determined to what degree the cellular immunity
was enhanced by the booster vaccination with the rFPV,
or how long the enhanced cellular immunity is main-
tained in chickens.
This study clearly indicates that strong and long-last-
ing protective immunity could be easily generated by the
dual-viral vector approach through a booster phenome-
non. Since the immunity was much quicker and stronger
than that induced by other immunization approaches, the
dual-viral vector approach has the following merits. First,
it is useful not only in controlling multiple infectious
diseases but also for analyzing the protective immunity
against antigens. Expression of immunomodulating cy-
tokines of Th1 or Th2 types along with protective anti-
gens in both viral vectors may provide insights into the
roles of cytokines in protective immunity. Second, since
replication of the booster vaccine was scarcely inter-
ferred by the primary vaccination, the strategy may be
applicable to other vector combinations. For example,
herpesvirus-primed and adenovirus-boosted immuniza-
tion regimens may generate strong mucosal immunity
against gastroenteric pathogens. These studies may al-
low us to design targeting induction of local protective
immunity in animals. Third, this approach is advanta-
geous for inducing strong protective immunity in large
animals such as chimpanzees, pigs, and cattle. It is
especially interesting to apply this approach to a study of
HIV vaccination.
In summary, this study shows that the herpesvirus-
primed and poxvirus-boosted immunization strategy is
an efficient means of safely inducing strong and long-
lasting protective immunity against a wide range of in-
fectious diseases in animals. The dual-vector approach
is also useful for analyzing host-protective immunity, and
other viral vector combinations may be applicable. Our
rMDV-primed and rFPV-boosted vaccine regimen is a
new experimental approach for studying the induction of
strong and long-lasting protective immunity against fetal
infectious diseases in chickens.
MATERIALS AND METHODS
Cells and viruses. Chick embryo fibroblast (CEF) cul-
tures were prepared from 10-day-old embryos of white
Leghorn line M (Nippon Institute of Biological Science,
Tokyo, Japan) and grown in Dulbecco’s MEM (Nissui,Tokyo, Japan), 5% fetal calf serum, 10% tryptose phos-
phate broth, and antibiotics.
A large-plaque variant of FPV (Nazerian et al., 1989),
originally derived from a vaccine strain (CEVA Labora-
tory, Overland Park, KS), was used for the generation of
rFPV. Recombinant MDV expressing IBDV host-protec-
tive antigen VP2 (from 1 to 453 aa of Seg. A ORF) (rMDV)
(Tsukamoto et al., 1999) and the parental MDV CVI-988
strains were used. These FPV, rFPV, MDV, and rMDV
were propagated in CEFs. The vvIBDV Ehime/91 strain
(Tsukamoto et al., 1992) was used as a challenge virus.
Two commercial live IBDV vaccines, IBDV-A and IBDV-C,
were used in a challenge experiment.
Transfer plasmid vector for rFPV. The VP2 gene (from 1
to 453 aa of Seg. A ORF) of the vvIBDV Ehime/91 strain
(GenBank Accession No. AB024076) was amplified by
PCR using primers with unique restriction sites (59-
GATCCCCCGCAGCGATGACGAACCTGCAAGATC-39
nd 59-GTCGACTCACCTCCTTAGGGCCCGAATTATG-39)
nd subcloned into a pNZ1729R digested with BamHI
nd SalI under the control of an FPV synthetic promoter
Yanagida et al., 1992). The resulting plasmid, pNZ29R/IBD-
P2, which had a nonessential FPV gene for replication
nd a lacZ reporter gene, was used as a transfer vector.
Construction of rFPV. The rFPV was constructed as
reviously described (Yanagida et al., 1992). CEF mono-
ayers (107 cells) were infected with FPV at a multiplicity
of infections of 0.1 and incubated for 4 h. The cells were
trypsinized, washed twice in saline G (0.14 M NaCl, 5 mM
KCl, 1.1 mM Na2HPO4, 1.5 mM KH2PO4, 0.5 mM MgCl2,
.01% glucose), and resuspended in 0.7 ml of saline G.
his cell suspension was mixed with 10 mg of the trans-
fer vector and subjected to electroporation at 1.2 kV, 25
mF, 0.4 ms, using a Cell-Porator apparatus (Bio-Rad Gene
Pulser). Transfected cells were plated onto a 6-cm-diam-
eter culture dish and incubated at 37°C. After 3 days,
these cells were harvested by scraping and disrupted by
freezing and thawing to release progeny viruses. Recom-
binant FPV was cloned three times by a limiting dilution
method by monitoring the lacZ activity with Bluo-gal (1
mg/ml, Gibco/BRL). The resulting virus was named rFPV.
PCR amplification of VP2 gene from rFPV. To determine
whether the rFPV contains the VP2 gene, the entire VP2
gene was amplified by a PCR with two primers, P-IBD1
(59-ATGACAAACCTGCAAGATCAAACCCA-39) and P-IBD2
(59-TTACCTCCTTATAGCCCGGATTATGT-39). Using the
QIAamp blood kit (Qiagen, Germany), rFPV DNA was
prepared from the culture fluid of the rFPV-infected CEFs
and used as the template for PCR analyses.
Western blotting (WB) analysis. WB analysis was car-
ried out as previously described (Tsukamoto et al., 1999).
CEF cells were infected with the wt FPV or rFPV, har-
vested 24 h later, and stored at 280°C before use. The
cells were subjected to a sodium dodecyl sulfate (SDS)-
12.5% polyacrylamide gel electrophoresis (PAGE) fol-
lowed by a transfer of the proteins to a nitrocellulose
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265DUAL-VIRAL VECTORS FOR INFECTIOUS BURSAL DISEASE VIRUSmembrane. The membrane was incubated with rabbit
anti-IBDV antiserum followed by horseradish peroxidase
(HRPO)-conjugated goat anti-rabbit IgG. The VP2 band
was detected by enhanced chemiluminescence (ECL)
Western blotting detection reagents (Amersham, Buck-
inghamshire, England).
Protection against vvIBDV. One-day-old white leghorn
SPF chickens were assigned to seven groups of 10 or 15
chickens each and reared in negative-pressure isolator
set in a negative-pressure chicken house. Each chicken
in Group 1 was vaccinated subcutaneously with the rFPV
(104 PFU/chick) at 14 days of age. Group 2 was vacci-
nated subcutaneously with the rMDV (104 PFU/chick) at 1
ay of age. Group 3 was vaccinated with both rMDV and
FPV at 1 day of age (rMDV-rFPV1d). Group 4 was vacci-
nated with the rMDV at 1 day of age followed by the rFPV
at 14 days of age (rMDV-rFPV14d). Group 5 was vacci-
nated orally with one dose of a live IBDV vaccine IBDV-A
at 20 days of age. The remaining two groups of 10
chickens each were used as challenge control and un-
inoculated control. All of the chickens were bled at 30
days of age, and the sera were stored at 220°C. The
chickens were then challenged orally with the vvIBDV
Ehime/91 strain (105 50% of egg infective dose (EID50)/
chick). Clinical signs and mortality were observed daily
for 7 days, and both dead and surviving chickens that
were sacrificed were subjected to gross and histopatho-
logical examinations of the BF. The histopathological BF
lesion scores were classified into five categories [1–5],
from mild to severe lesions as previously described
(Tsukamoto et al., 1995b). BF lesion scores 0 or 1 mean
hat the vvIBDV replication is almost completely sup-
ressed; scores 2 to 4 mean that replication of the
hallenge virus is suppressed to the level equal to that of
he vaccine strain replication; score 5 means that the
hallenge virus replicates considerably. Economic loss
n farms is caused only in chickens with lesion score 5.
hickens with BF lesion scores of 0–4, which were also
bserved in chickens infected with live vaccine strains
Tsukamoto et al., 1995b), were considered protected
istopathologically (Tsukamoto et al., 1999).
In a separate experiment, to see the side effects of live
accine IBDV-C, ten 30-day-old SPF chickens were vac-
inated orally with one dose of IBDV-C. At 37 days old,
he BF gross lesion and histopathological lesion score
ere determined as described above.
Detection of antibodies to IBDV VP2 and MDV. Anti-
odies against IBDV VP2 were detected by an enzyme
mmunoassay (EIA) as previously described (Tsukamoto
t al., 1999). For the EIA, CEF-adapted J1CEF72 strain of
IBDV (3 3 106 PFU) was inoculated onto primary CEF
ells (8 3 106 cells) in a 96-well plate (Falcon, Lincoln
ark, NJ), and the cells were cultured for 20 h. After
insing the cells with phosphate-buffered saline (PBS),
he cells were fixed with a fixation solution (80% acetone
n water) for 5 min, and the antigen-coated plates were
V
ttored at 280°C before use. Serum samples were di-
uted with a diluent (5% skim milk powder/PBS) and
dded to wells coated with acetone-fixed IBDV-infected
EF cells. After incubation for 1 h at 37°C and subse-
uent washing of the cells, the plates were incubated
ith HRPO-conjugated goat anti-chicken IgG (Fc) (1:1000
ilution with the diluent; Bethyl Lab., Inc., Montgomery,
X) for 30 min at 37°C. After washing, the substrate
3,39-diaminobenzidine tetrahydrochloride) was added,
nd the plate was incubated for 10 min. The stained cells
ere observed under a light microscope. Agar gel pre-
ipitation (AGP) antibodies to VP2 were also detected
sing BF homogenate antigen prepared from chickens
nfected with the IBDV E/91 strain as previously de-
cribed (Tsukamoto et al., 1999).
Antibody titers to MDV were tested by EIA using CEF
ells infected with the CVI-988 strain as the antigen as
reviously described (Tsukamoto et al., 1999).
Persistence of humoral immunity in chickens. To de-
ermine how long the vaccine immunity to IBDV VP2
ontinued in the vaccinated chickens, sera were tested
or the presence of the antibodies. One-day-old SPF
hickens were assigned to three groups of 5 chickens
ach and were leg-banded.
Two groups were vaccinated at 1 day old with the
MDV (104 PFU/chick) (rMDV group), and one of the
groups was further vaccinated with the rFPV-VP2 (104
PFU/chick) at 2 weeks of age (rMDV-rFPV14d group). The
third group of chickens was vaccinated orally with one
dose of live vaccine IBDV-A at one week of age (IBDV-A
group). Each group of chickens was reared in a negative-
pressure isolator for 28 weeks, and the sera were col-
lected every 4 weeks and stored at 220°C. The sera
were used for detecting anti-VP2 antibodies by the AGP
tests because the AGP antibody was highly correlated
with the protection (Fig. 3C). These sera were also tested
for anti-MDV antibodies by the EIA test.
Persistence of rMDV in chickens. Both first and nested
PCR assays were used to determine the persistence of
the rMDV in chickens vaccinated with the rMDV followed
by boosting with the rFPV. Chickens vaccinated with the
rMDV alone were used as the control. The PCR analyses
were performed on IBDV VP2 and MDV US2 genes of the
rMDV using chicken lymphocyte DNA as the templates.
At 28 weeks of age, peripheral blood lymphocytes were
taken, and the cellular DNA was purified with a QIAamp
blood kit (Qiagen, Germany) and used as a template for
the PCR. The entire VP2 region (1.35 kbp) was amplified
with two primers, P-IBD1 (59-ATGACAAACCTGCAAGAT-
CAAACCCA-39) and P-IBD2 (59-TTACCTCCTTATAGC-
CCGGATTATGT-39), and the internal region (0.45 kbp)
was further amplified by the nested PCR with two prim-
ers, P-IBD15 (59-CCCAGAGTCTACACCATA-39) and
-IBD16 (59-TCCTGTTGCCACTCTTTC-39). Same as the
P2, the MDV US2 region (0.7 kbp) was amplified with
wo primers, P-MD1 (59-GGTTGTAGCGATGCACCTAAT-
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266 TSUKAMOTO ET AL.39) and P-MD16 (59-TCTTCCTCGGCAACATCGACC-39),
nd the internal region (0.4 kbp) was further amplified by
he nested PCR with two primers, P-MD15 (59-TGTAT-
CGTGACTTTCCTGTC-39) and P-MD6 (59-AATGCTCCA-
ATAGCTTGTGG-39). Both first and nested PCR condi-
ions are as follows: 1 cycle of 94°C for 1 min; 35 cycles
f 94°C for 1 min, 50°C for 1 min, and 72°C for 2 min; and
cycle of 72°C for 7 min.
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